Isofol Medical AB
ISOFOL.XSTO
Isofol Medical AB is a biotechnology company that develops advanced cancer therapies, focusing primarily on oncology. Isofol Medical AB aims to enhance the efficacy of current standard chemotherapy treatments through its novel drug candidate, arfolitixorin, designed to improve the therapeutic outcomes for patients with metastatic colorectal cancer. The company is deeply involved in the pharmaceutical and medical research industries, contributing significantly to the development of innovative cancer treatment options. Based in Sweden, Isofol collaborates with various academic and clinical institutions to further its research efforts and bring new, effective therapies to market. The company is a crucial player in the biotechnology sector, emphasizing its commitment to addressing unmet medical needs and advancing cancer care. By focusing on improving existing treatments, Isofol Medical AB plays an essential role in enhancing the quality of life for cancer patients, making it a vital entity in the ongoing fight against this challenging disease.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
kr 0.00
Net Income (TTM)
-kr 57M
▼ -24.6% YoY
Op. Margin
–
ROIC
-47.60%
▼ -10.2pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-kr 53M
▼ -23.7% YoY
Op. Cash Flow (TTM)
-kr 53M
▼ -24.4% YoY
Net Debt
-kr 127M
Net Cash Position
Cash & Equiv.
kr 127M
Continue Research
Peers
Biotechnology · Pick stocks to compare with ISOFOL.XSTO
Isofol Medical AB (ISOFOL.XSTO) in three numbers
Questions about Isofol Medical AB
Is Isofol Medical AB a high-quality business?
Isofol Medical AB scores 10 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 4 checks computed from company filings. Its best check is net debt at -$127M, and its weakest is return on capital at -47.6%. The Quality tab shows every check against its target.
Does Isofol Medical AB (ISOFOL.XSTO) pay a dividend?
No. Isofol Medical AB (ISOFOL.XSTO) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: company filings. Price: last close 6 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing ISOFOL.XSTO
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.